{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T06:59:58Z","timestamp":1649055598410},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Ziel\u2002Retrospektive Auswertung von Registerdaten des PneuNET-Registers Berlin zur Erfassung des klinischen Verlaufes typischer und atypischer Karzinoide (bpNET).<\/jats:p><jats:p>\n          Methode\u2002Im Zeitraum von 2007\u200a\u2013\u200a2016 wurden klinikeigene Tumordatenbanken aus 3 Berliner Zentren systematisch nach der Diagnose Karzinoid durchsucht. Einschlusskriterien waren: das Vorliegen eines neuroendokrinen Lungentumors im Sinne eines typischen oder atypischen Karzinoids, Alter &gt;\u200a18 Jahre und erfasster Erkrankungsverlauf \u00fcber mindestens 2 Jahre oder Tod zuvor. Daten bez\u00fcglich epidemiologischer Parameter wie H\u00e4ufigkeit, Geschlecht, biologischer Aktivit\u00e4t, Raucherstatus, Tumorlokalisation, Biomarker, Folgediagnostik sowie Therapie und Nachsorge wurden ausgewertet.<\/jats:p><jats:p>\n          Ergebnisse\u2002Ab dem 01.\u200a01.\u200a2007 wurden retrospektiv 187 Patienten mit der Erstdiagnose eines bronchopulmonalen Karzinoids erfasst, wobei das Verh\u00e4ltnis von TC zu AC 8:2 betrug. Das mediane Erkrankungsalter lag bei 65,4 Jahren, 64\u200a% der Patienten waren Frauen. 10,7\u200a% der Patienten wiesen eine pulmonale Symptomatik auf, bei 2 Patienten zeigte sich ein Karzinoidsyndrom, ein MEN-1-Syndrom wurde bei keinem Patienten nachgewiesen. 87,7\u200a% der Patienten erhielten eine operative Therapie, dabei \u00fcberwog mit 69,5\u200a% die Lobektomie mit systematischer Lymphadenektomie. Lediglich 10\u200a% der Patienten wurden prim\u00e4r im Tumorstadium IV erstdiagnostiziert, hier \u00fcberwogen die Patienten mit AC. Die Systemtherapie war uneinheitlich und umfasste neben der Chemotherapie die Therapie mit Everolimus und Somatostatinrezeptoranaloga.<\/jats:p><jats:p>\n          Schlussfolgerungen\u2002Bronchopulmonale Karzinoide geh\u00f6ren zu den gut differenzierten neuroendokrinen Tumoren der Lunge und werden \u00fcberwiegend in einem fr\u00fchen Erkrankungsstadium mit m\u00f6glichem lokalen Therapieansatz und resultierender guter Prognose diagnostiziert. Bei Nachweis eines metastasierten Tumorstadiums stehen mit dem mTOR-Inhibitor Everolimus oder Somatostatinrezeptoranaloga systemische Therapieoptionen zur Verf\u00fcgung. Aufgrund der insgesamt seltenen Tumorerkrankung ist eine systematische Erfassung der Patienten im NET-Register zur Erhebung prospektiver Daten und der Erarbeitung eines einheitlichen Diagnostik- und Therapiealgorithmus sinnvoll.<\/jats:p>","DOI":"10.1055\/a-1237-3617","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T23:38:52Z","timestamp":1611013132000},"page":"276-283","source":"Crossref","is-referenced-by-count":0,"title":["Klinischer Verlauf typischer und atypischer Karzinoide (bpNET) \u2013 Auswertung von Registerdaten des PneuNET-Registers Berlin zur Identifikation von Indikatoren zur Prognosebestimmung und Therapieplanung"],"prefix":"10.1055","volume":"75","author":[{"given":"S.","family":"Kurz","sequence":"additional","affiliation":[{"name":"Evangelische Lungenklinik Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Helios Klinikum Emil von Behring \u2013 Lungenklinik Heckeshorn"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"DRK-Kliniken Berlin, Lungenklinik Mitte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Schneider","sequence":"additional","affiliation":[{"name":"DRK-Kliniken Berlin, Lungenklinik Mitte"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Utzig","sequence":"additional","affiliation":[{"name":"DRK-Kliniken Berlin, Lungenklinik Mitte, Klinik f\u00fcr Thoraxchirurgie"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Groh\u00e9","sequence":"additional","affiliation":[{"name":"Evangelische Lungenklinik Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.002","article-title":"Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors","author":"P Robelin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000457956","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification","volume":"105","author":"A Perren","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"M E Caplin","year":"2015","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000457957","article-title":"ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors","volume":"105","author":"M Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000472254","article-title":"ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers","volume":"105","author":"K Oberg","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/JTO.0b013e31818b06e3","article-title":"The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer","volume":"3","author":"W D Travis","year":"2008","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/030089161009600532","article-title":"The ENETS guidelines: the new TNM classification system","volume":"96","author":"G Rindi","year":"2010","journal-title":"Tumori"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging","volume":"105","author":"A Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000473892","article-title":"Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy","volume":"105","author":"R Garcia-Carbonero","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000471880","article-title":"Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents","volume":"105","author":"M Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000402752","article-title":"Medical Therapy of Pulmonary Neuroendocrine Neoplasms: Targeted, Symptomatic and Chemotherapy","volume":"44","author":"P Ferolla","year":"2015","journal-title":"Front Horm Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"J C Yao","year":"2016","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cas.13427","article-title":"Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis","volume":"109","author":"N Fazio","year":"2018","journal-title":"Cancer Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"P Ferolla","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues","volume":"105","author":"R J Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000458155","article-title":"ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation","volume":"105","author":"U Knigge","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jtho.2018.02.002","article-title":"New Insights intothe Molecular Characteristics of Pulmonary Carcinoids and Large CellNeuroendocrine Carcinomas, and the Impact on Their Clinical Management","volume":"13","author":"J L Derks","year":"2018","journal-title":"J Thorac Oncol"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1237-3617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T09:18:40Z","timestamp":1621243120000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1237-3617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":17,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,4,19]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1237-3617","relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"value":"0934-8387","type":"print"},{"value":"1438-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]}}}